2016, doi: 10.1111/andr.12191
In a phase 2a clinical trial (NCT03976401), treatment of Efruxifermin in NASH patients (F1-F3 stage) indicated that the absolute changes from baseline in hepatic fat fraction were decreased in a dose-dependent manner, namely 12.3% (28 mg), 13.4% (50 mg), and 14.1% (70 mg) compared to 0.3% in the placebo group
She took the time to thoroughly explain my condition and the treatment options available, ensuring I felt comfortable and informed every step of the way
Trastuzumab deruxtecan versus treatment of physicians choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Luo Y, Han Z, Chin SM, Linn S (1994) Three chemically distinct types of oxidants formed by iron-mediated Fenton reactions in the presence of DNA